Product Description
Argatroban is a medication used to manage heparin-induced thrombocytopenia (HIT), which is a rare, life-threatening complication of heparin therapy. It is a direct thrombin inhibitor, a class of anticoagulant drugs. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK555971/)
Mechanisms of Action: DT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Canada | China | Denmark | Egypt | Finland | France | Germany | Greece | India | Italy | Japan | Korea | Malta | Netherlands | Norway | Romania | Saudi Arabia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States
Approved Indications: Coronary Thrombosis | Thrombosis | Thrombocytopenia | Coronary Thrombosis | Thrombosis | Thrombocytopenia
Known Adverse Events: Cardiac Arrest | Hypotension | Back Pain | Chest Pain | Headache | Pain Unspecified | Dyspnea | Diarrhea | Sepsis
Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Thrombocytopenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VLX-1005-002 | P1 |
Completed |
Thrombocytopenia |
2022-04-01 |
21% |
| VLX-1005-002 | P1 |
Completed |
Thrombocytopenia |
2022-04-01 |
21% |